BR112015020716A2 - processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto - Google Patents
processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e compostoInfo
- Publication number
- BR112015020716A2 BR112015020716A2 BR112015020716A BR112015020716A BR112015020716A2 BR 112015020716 A2 BR112015020716 A2 BR 112015020716A2 BR 112015020716 A BR112015020716 A BR 112015020716A BR 112015020716 A BR112015020716 A BR 112015020716A BR 112015020716 A2 BR112015020716 A2 BR 112015020716A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- oxazepin
- methylpropanamide
- dihydrobenzo
- imidazo
- Prior art date
Links
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229950001269 taselisib Drugs 0.000 abstract 2
- 239000012828 PI3K inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779619P | 2013-03-13 | 2013-03-13 | |
| PCT/EP2014/054786 WO2014140073A1 (en) | 2013-03-13 | 2014-03-12 | Process for making benzoxazepin compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015020716A2 true BR112015020716A2 (pt) | 2017-07-18 |
Family
ID=50241450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015020716A BR112015020716A2 (pt) | 2013-03-13 | 2014-03-12 | processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9303043B2 (https=) |
| EP (3) | EP3845540A1 (https=) |
| JP (6) | JP6363120B2 (https=) |
| KR (3) | KR101871133B1 (https=) |
| CN (2) | CN108929333A (https=) |
| AR (1) | AR095365A1 (https=) |
| AU (3) | AU2014230812B2 (https=) |
| BR (1) | BR112015020716A2 (https=) |
| CA (6) | CA2897618A1 (https=) |
| IL (1) | IL240793A0 (https=) |
| MX (1) | MX2015011438A (https=) |
| NZ (1) | NZ711192A (https=) |
| RU (2) | RU2018109979A (https=) |
| SG (2) | SG10201706760YA (https=) |
| WO (1) | WO2014140073A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180093138A (ko) | 2013-12-16 | 2018-08-20 | 에프. 호프만-라 로슈 아게 | 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도 |
| AU2016287463B2 (en) | 2015-07-02 | 2020-07-02 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| CN111848643A (zh) | 2015-07-02 | 2020-10-30 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
| CN105906635A (zh) * | 2016-06-08 | 2016-08-31 | 上海大学 | 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法 |
| KR20190036549A (ko) * | 2016-07-29 | 2019-04-04 | 니뽄 다바코 산교 가부시키가이샤 | 피라졸-아미드 화합물의 제조 방법 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| WO2018109204A1 (en) | 2016-12-15 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide |
| CN108752237A (zh) * | 2018-07-05 | 2018-11-06 | 四川青木制药有限公司 | 一种对氨基苯甲脒盐酸盐的新制备方法 |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| WO2000024720A1 (en) * | 1998-10-23 | 2000-05-04 | Dow Agrosciences Llc | 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds |
| KR20040024564A (ko) | 2001-07-12 | 2004-03-20 | 아베시아 리미티드 | 마이크로캡슐화된 촉매, 이의 제조 방법 및 이의 사용 방법 |
| JP2005507932A (ja) * | 2001-10-12 | 2005-03-24 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満の処置のためのフェニル置換５−員窒素含有複素環 |
| JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| BRPI0717320A2 (pt) * | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| KR101083177B1 (ko) * | 2006-10-23 | 2011-11-11 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 트리아졸로-피리다진 단백질 키나제 조정제 |
| JP2010516680A (ja) * | 2007-01-19 | 2010-05-20 | エックスカバリー，インコーポレイテッド | キナーゼ阻害薬化合物 |
| JP5348725B2 (ja) * | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| US8716483B2 (en) * | 2008-02-21 | 2014-05-06 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| MX2010010659A (es) | 2008-03-31 | 2010-10-26 | Genentech Inc | Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos. |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| US8263633B2 (en) | 2009-09-28 | 2012-09-11 | F. Hoffman-La Roche Ag | Benzoxepin PI3K inhibitor compounds and methods of use |
| MY160064A (en) | 2009-09-28 | 2017-02-15 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
| WO2011053688A1 (en) * | 2009-10-29 | 2011-05-05 | Schering Corporation | Bridged bicyclic piperidine derivatives and methods of use thereof |
| CN102558167A (zh) * | 2010-12-29 | 2012-07-11 | 中国医学科学院药物研究所 | Gk和ppar双重激动活性的噻唑烷二酮衍生物 |
| US9090628B2 (en) | 2011-03-21 | 2015-07-28 | Genentech, Inc. | Benzoxazepin compounds selective for PI3K P110 delta and methods of use |
| NO3175985T3 (https=) * | 2011-07-01 | 2018-04-28 | ||
| BR112014028376A2 (pt) | 2012-06-08 | 2018-04-24 | Hoffmann La Roche | métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção |
-
2014
- 2014-03-12 MX MX2015011438A patent/MX2015011438A/es unknown
- 2014-03-12 NZ NZ711192A patent/NZ711192A/en not_active IP Right Cessation
- 2014-03-12 CA CA2897618A patent/CA2897618A1/en not_active Abandoned
- 2014-03-12 SG SG10201706760YA patent/SG10201706760YA/en unknown
- 2014-03-12 EP EP20204345.1A patent/EP3845540A1/en active Pending
- 2014-03-12 CA CA2948765A patent/CA2948765A1/en not_active Abandoned
- 2014-03-12 KR KR1020177016062A patent/KR101871133B1/ko not_active Expired - Fee Related
- 2014-03-12 SG SG11201507394RA patent/SG11201507394RA/en unknown
- 2014-03-12 RU RU2018109979A patent/RU2018109979A/ru not_active Application Discontinuation
- 2014-03-12 CA CA2948763A patent/CA2948763C/en not_active Expired - Fee Related
- 2014-03-12 CA CA3005112A patent/CA3005112A1/en not_active Abandoned
- 2014-03-12 JP JP2015562108A patent/JP6363120B2/ja active Active
- 2014-03-12 KR KR1020187016976A patent/KR20180070715A/ko not_active Withdrawn
- 2014-03-12 CN CN201810489045.8A patent/CN108929333A/zh active Pending
- 2014-03-12 WO PCT/EP2014/054786 patent/WO2014140073A1/en not_active Ceased
- 2014-03-12 BR BR112015020716A patent/BR112015020716A2/pt not_active Application Discontinuation
- 2014-03-12 EP EP18173513.5A patent/EP3404032B1/en active Active
- 2014-03-12 CN CN201480015055.8A patent/CN105377856B/zh active Active
- 2014-03-12 EP EP14709314.0A patent/EP2970329A1/en not_active Withdrawn
- 2014-03-12 AR ARP140100904A patent/AR095365A1/es unknown
- 2014-03-12 KR KR1020157024484A patent/KR101821468B1/ko not_active Expired - Fee Related
- 2014-03-12 RU RU2015138488A patent/RU2649976C2/ru not_active IP Right Cessation
- 2014-03-12 CA CA3005103A patent/CA3005103A1/en not_active Abandoned
- 2014-03-12 CA CA3005118A patent/CA3005118A1/en not_active Abandoned
- 2014-03-12 AU AU2014230812A patent/AU2014230812B2/en not_active Ceased
- 2014-03-12 US US14/205,634 patent/US9303043B2/en active Active
-
2015
- 2015-08-24 IL IL240793A patent/IL240793A0/en unknown
-
2016
- 2016-06-28 AU AU2016204432A patent/AU2016204432B2/en not_active Ceased
-
2017
- 2017-07-10 JP JP2017135083A patent/JP6442005B2/ja active Active
-
2018
- 2018-02-27 AU AU2018201393A patent/AU2018201393A1/en not_active Abandoned
- 2018-03-12 JP JP2018044050A patent/JP2018150298A/ja active Pending
- 2018-08-16 JP JP2018153231A patent/JP6663459B2/ja active Active
- 2018-11-22 JP JP2018219226A patent/JP2019089762A/ja active Pending
-
2020
- 2020-02-28 JP JP2020032846A patent/JP2020114814A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015020716A2 (pt) | processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto | |
| BR112016014018B8 (pt) | Processo para a preparação dos compostos de cetona (ia), e processo para a preparação dos compostos de triazol de fórmula (ic) | |
| BR112015019627A2 (pt) | amidas heterocíclicas como inibidores de quinases | |
| CR20130470A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA | |
| CU24354B1 (es) | Procedimiento de obtención de derivados de tetrafluoropropilmorfolina | |
| GT201300078A (es) | Proceso para la preparacion de inhibidores de pan-cdk de la formula ( i ), e intermediarios de la preparacion | |
| BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
| BR112015005694A2 (pt) | pró-fármacos de inibidor amino-quinazoliníco de quinase | |
| AR098394A1 (es) | Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2) | |
| BR112017028322A2 (pt) | compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i | |
| BR112014010997A2 (pt) | processo para o preparo de ß-glicosídeos de c-arila | |
| UA116801C2 (uk) | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2 | |
| UY35746A (es) | Derivados de fenilalanina sustituidos | |
| BR112015014822A2 (pt) | compostos de fórmula i, composição, utilização de um composto, método para o combate dos fungos nocivos e semente revestida | |
| MX369323B (es) | Pildoras de desfluidización solubles en acido. | |
| BRPI1006408A2 (pt) | processo para a preparação de derivados de pirazol de fórmula (i) | |
| CR20150006A (es) | Metodo para preparar triazolopiridinas sustituidas | |
| BR112015015798B8 (pt) | Método para a preparação de um composto de fórmula 1 | |
| BR112016009665A8 (pt) | polimorfos, composição farmacêutica, processos para a preparação de um polimorfo e usos dos polimorfos | |
| MX2020009462A (es) | Procesos para la preparación de compuestos de pirimidinilciclopentano. | |
| BR112016016397A2 (pt) | método para preparar 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carbaldeídos e 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carboxilatos. | |
| BR112015031945A2 (pt) | processos para a preparação de compostos | |
| EP2964210A4 (en) | PROCESS FOR THE PREPARATION OF 2-AMINO-1,3-PROPANEDIOL COMPOUNDS AND SALTS THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |